ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 099,64
-0,51%
Dow Jones
39 872,99
0,17%
DAX
18 661,31
-0,35%
Brent Oil
81,68
-0,93%
Bitcoin
69 698,31
-0,62%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Exelixis Inc (EXEL)

  7. Exelixis Inc (EXEL) Actualités

EXEL

Exelixis (EXEL)

Exelixis Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EXEL
DateHeureSourceTitreSymboleSociété
21/05/202423h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXELExelixis Inc
20/05/202422h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EXELExelixis Inc
20/05/202414h00Business WireExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USANASDAQ:EXELExelixis Inc
18/05/202401h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
08/05/202422h11Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EXELExelixis Inc
07/05/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MayNASDAQ:EXELExelixis Inc
30/04/202422h05Business WireExelixis Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
16/04/202422h05Business WireExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024NASDAQ:EXELExelixis Inc
27/02/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in MarchNASDAQ:EXELExelixis Inc
13/02/202415h19Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EXELExelixis Inc
06/02/202422h49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EXELExelixis Inc
06/02/202422h05Business WireExelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
01/02/202422h05Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in FebruaryNASDAQ:EXELExelixis Inc
25/01/202414h00Business WireExelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024NASDAQ:EXELExelixis Inc
23/01/202422h05Business WireExelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024NASDAQ:EXELExelixis Inc
22/01/202423h00Business WireOpdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
18/01/202422h05Business WireEuropean Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) TabletsNASDAQ:EXELExelixis Inc
10/01/202403h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EXELExelixis Inc
07/01/202422h00Business WireExelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024NASDAQ:EXELExelixis Inc
02/01/202422h05Business WireExelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024NASDAQ:EXELExelixis Inc
07/12/202322h05Business WireExelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023NASDAQ:EXELExelixis Inc
04/12/202314h02Business WireExelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck CancerNASDAQ:EXELExelixis Inc
04/12/202314h00Business WireExelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell CarcinomaNASDAQ:EXELExelixis Inc
21/11/202322h05Business WireExelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023NASDAQ:EXELExelixis Inc
10/11/202315h00Business WireExelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023NASDAQ:EXELExelixis Inc
01/11/202321h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EXELExelixis Inc
01/11/202321h05Business WireExelixis Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:EXELExelixis Inc
22/10/202308h30Business WireDetailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023NASDAQ:EXELExelixis Inc
18/10/202322h05Business WireExelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023NASDAQ:EXELExelixis Inc
12/09/202314h00Business WireExelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 InhibitorNASDAQ:EXELExelixis Inc
 Showing the most relevant articles for your search:NASDAQ:EXEL

Dernières Valeurs Consultées

EU
ORA
Orange
EU
EN
Bouygues
NASDAQ
MSFT
Microsoft
EU
GLE
Societe Generale
NASDAQ
GOOGL
Alphabet
EU
VIV
Vivendi
EU
AF
Air FranceKLM
EU
ML
Michelin
NYSE
MRK
Merck
USI
USTECH100
US Tech 100
EU
LR
Legrand
NYSE
NKE
Nike
NYSE
MCD
McDonalds
EU
VK
Vallourec
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés